@article{article, title  = {{484 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial}},

 url = {{}},

 year = {{2021}},

 month = {{5}},

 author = {{Paller A and Cork MJ and Marcoux D and Zhang H and Chuang C and Zhang A and Chao J}},

 doi = {{10.1016/j.jid.2021.02.508}},

 volume = {{141}},

 journal = {{Journal of Investigative Dermatology}},

 issue = {{5}},

 pages = {{s84}},

 note = {{Accessed on 2024/12/22}}}